<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02633137</url>
  </required_header>
  <id_info>
    <org_study_id>15-196</org_study_id>
    <nct_id>NCT02633137</nct_id>
  </id_info>
  <brief_title>Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma</brief_title>
  <official_title>Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma: A Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out what effects, good and/or bad, the treatment&#xD;
      including 1) Lenalidomide-RCHOP, 2) R-HIDAC, and 3) Lenalidomide-Rituximab maintenance has on&#xD;
      the participant and their lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will receive lenalidomide 15 mg orally daily on days 1-14 with standard-dose R-CHOP&#xD;
      (375 mg/m^2 intravenous rituximab, 750 mg/m2 intravenous cyclophosphamide, 50 mg/m^2&#xD;
      intravenous doxorubicin, and 1.4 mg/m2 intravenous vincristine on day 1, and 100 mg&#xD;
      prednisone days 1-5 or days 2-6) every 21 days for four cycles.&#xD;
&#xD;
      All patients will receive pegfilgrastim on day 2 of each cycle and aspirin 81 mg orally daily&#xD;
      for venous thromboembolism prophylaxis throughout the four cycles.&#xD;
&#xD;
      After four cycles of Len-RCHOP, the patients will undergo restaging PET/CT scans. Patients&#xD;
      with evidence of disease progression will be treated off study.&#xD;
&#xD;
      R-HIDAC After lenalidomide-RCHOP phase, patients without evidence of progressive disease will&#xD;
      receive rituximab 375 mg/m^2 day 1 and then patients will be admitted for high-dose&#xD;
      cytarabine (HIDAC). Recommended age-adjusted HIDAC doses are as follows: ≤65 years: 3 g/m2&#xD;
      every12 hours X 4 doses; 65-70 years: 2 g/m^2 every12 hours X 4 doses; &gt;70 years: 1 g/m^2&#xD;
      every12 hours X 4 doses. Physician discretion will dictate the choice of HIDAC dose, ranging&#xD;
      from 1 g/m^2 - 3 g/m^2 every 12 hours X 4 doses.&#xD;
&#xD;
      Patients will receive two cycles of rituximab-HIDAC every 3 weeks. After two cycles of&#xD;
      R-HIDAC, the patients will undergo restaging PET/CT scans. Patients with evidence of disease&#xD;
      progression will be treated off study.&#xD;
&#xD;
      Len-Rituximab Maintenance After completion of induction chemotherapy with Len-RCHOP and&#xD;
      R-HIDAC, patients will begin maintenance phase with lenalidomide and rituximab for 6 months.&#xD;
      Lenalidomide will be administered at 15 mg orally daily on days 1-21 of a 28-day cycle for a&#xD;
      total of 6 cycles and rituximab maintenance every 8 weeks for a total of 3 treatments.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 14, 2015</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3-year progression-free survival (PFS)</measure>
    <time_frame>3 years</time_frame>
    <description>acceptable 3-yr PFS as 75% or higher, and unacceptable rate as 60% or lower.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Mantle Cell Lymphoma</condition>
  <condition>Untreated</condition>
  <arm_group>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lenalidomide + R-CHOP x 4 cycles R-HiDAC x 2 cycles R-Len maintenance x 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <arm_group_label>Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R-CHOP</intervention_name>
    <description>Rituximab 375 mg/m^2 IVPB with premedications Day 1&#xD;
Cyclophosphamide 750 mg/m^2 IVPB Day 1&#xD;
Doxorubicin 50 mg/m^2 IVP Day 1&#xD;
Vincristine 1.4 mg/m^2 IVP (capped at 2 mg) Day 1&#xD;
Prednisone 100 mg PO Daily on Days 1-5 or 2-6</description>
    <arm_group_label>Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>high-dose cytarabine (HIDAC)</intervention_name>
    <arm_group_label>Chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Previously untreated mantle cell lymphoma patients (at least clinical stage 2)&#xD;
&#xD;
          -  Histologic diagnosis confirmed by MSKCC pathologist as mantle cell lymphoma&#xD;
&#xD;
          -  Presence of evaluable disease&#xD;
&#xD;
          -  Age ≥18 years KPS ≥ 70%&#xD;
&#xD;
          -  Adequate organ function: ANC ≥1500 and platelet count ≥100,000, unless felt to be&#xD;
             secondary to underlying mantle cell lymphoma&#xD;
&#xD;
          -  Renal function assessed by calculated creatinine clearance as follows:&#xD;
&#xD;
          -  Cockcroft-Gault estimation of CrCl):&#xD;
&#xD;
               -  Calculated creatinine clearance ≥ 30ml/min by Cockcroft-Gault formula. See&#xD;
                  section below, &quot;Dosing Regimen&quot;, regarding lenalidomide dose adjustment for&#xD;
                  calculated creatinine clearance ≥30ml/min and &lt; 60ml/min.&#xD;
&#xD;
          -  Adequate hepatic function as determined by&#xD;
&#xD;
               -  Total bilirubin &lt;1.5X upper limit of normal (ULN) (unless known Gilbert syndrome)&#xD;
&#xD;
               -  AST (SGOT) and ALT (SGPT) 3 x ULN&#xD;
&#xD;
          -  All study participants must be registered into the mandatory Revlimid REMS® program,&#xD;
             and be willing and able to comply with the requirements of the REMS® program.&#xD;
&#xD;
          -  Females of reproductive potential must adhere to the scheduled pregnancy testing as&#xD;
             required in the Revlimid REMS® program.&#xD;
&#xD;
          -  Each subject must sign an informed consent form indicating that he or she understand&#xD;
             the purpose of and procedures required for the study and are willing to participate.&#xD;
&#xD;
          -  Short course systemic corticosteroids is permissible for disease control, improvement&#xD;
             of performance status or non-cancer indication if ≤ 10 days and must be discontinued&#xD;
             prior to study treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known central nervous system (CNS) lymphoma&#xD;
&#xD;
          -  Uncontrolled or severe cardiovascular disease or left ventricular ejection fraction&#xD;
             &lt;50% as determined by echocardiogram or MUGA.&#xD;
&#xD;
          -  Any life-threatening illness, medical condition, or organ system dysfunction which, in&#xD;
             the investigator's opinion, could compromise the subject's safety or put the study&#xD;
             outcomes at undue risk.&#xD;
&#xD;
          -  Pregnant or breast-feeding. Pre-menopausal patients must have a negative serum HCG&#xD;
             within 14 days of enrollment.&#xD;
&#xD;
          -  Patients using ≥20 mg/day of prednisone (or steroid equivalent dose) for any chronic&#xD;
             medical condition&#xD;
&#xD;
          -  Known seropositive, requiring anti-viral therapy, and with detectable viral load by&#xD;
             PCR for human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C&#xD;
             virus (HCV).&#xD;
&#xD;
          -  Known hypersensitivity to thalidomide or lenalidomide&#xD;
&#xD;
          -  The development of erythema nodosum if characterized by a desquamating rash while&#xD;
             taking thalidomide or similar drugs.&#xD;
&#xD;
          -  Patients planned for upfront consolidation with high-dose therapy and autologous stem&#xD;
             cell transplant.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anita Kumar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Basking Ridge</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Monmouth</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Bergen</name>
      <address>
        <city>Montvale</city>
        <state>New Jersey</state>
        <zip>07645</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Commack</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Westchester</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Nassau</name>
      <address>
        <city>Uniondale</city>
        <state>New York</state>
        <zip>11553</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mskcc.org/</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 15, 2015</study_first_submitted>
  <study_first_submitted_qc>December 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2015</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lenalidomide</keyword>
  <keyword>15-196</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

